Skip to main content

Table 1 Seroprevalence of severe acute respiratory syndrome coronavirus 2-specifc IgG and IgM antibodies

From: Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study

 

Sample size, N

Seropositive participants, n

Seroprevalence

 

Crude

(95% CI)

Weighted

(95% CI) a

Adjusted for test Scenario I

(95% CI)b

Adjusted for test Scenario II

(95% CI)c

P_value

Total

7411

1764

23.8 (22.8-24.8)

24.0 (21.8-26.2)

34.2 (31.0-37.3)

31.8 (28.8-34.7)

 

Sex

 Male

3721

876

23.5 (22.2-25.0)

23.7 (20.4-26.9)

33.6 (28.4-38.8)

31.2 (26.7-35.7)

0.597

 Female

3690

888

24.1 (22.7-25.5)

24.3 (21.5-27.1)

34.7 (30.5-38.9)

32.3 (28.4-36.1)

Age, years

 10-19

362

85

23.5 (19.2-28.2)

20.9 (14.7-27.2)

29.7 (20.1-39.4)

27.7 (18.7-36.6)

< 0.0001

 20-29

879

183

20.8 (18.2-23.7)

20.9 (17.2-24.7)

29.4 (23.9-35.0)

27.4 (21.7-33.1)

 30-39

2202

480

21.8 (20.1-23.6)

23.1 (19.2-26.9)

32.6 (26.5-38.8)

30.4 (24.6-36.1)

 40-49

2051

492

24.0 (22.1-25.9)

23.4 (19.9-26.8)

33.2 (27.9-38.4)

30.8 (26.0-35.7)

 50-59

1272

331

26.0 (23.6-28.5)

25.0 (21.1-29.0)

35.7 (29.4-42.0)

33.2 (27.4-39.0)

 ≥ 60

645

193

29.9 (26.4-33.6)

34.4 (28.1-40.6)

50.2 (40.7-59.7)

46.7 (38.5-54.9)

Comorbidity

 Yes

2229

561

25.2 (23.4-27.0)

23.7 (21.5-25.8)

32.4 (25.4-39.4)

30.1 (23.8-36.5)

0.062

 No

5123

1186

23.1 (22.0-24.3)

22.9 (18.3-27.5)

33.6 (30.3-37.0)

31.3 (28.1-34.4)

Contact with confirmed COVID-19 patients

 Yes

2557

730

28.5 (26.8-30.3)

29.5 (23.1-35.9)

42.6 (32.8-52.4)

37.0 (28.5-45.4)

< 0.0001

 No

4739

1010

21.3 (20.1-22.5)

21.3 (19.6-23.1)

30.0 (27.3-32.8)

26.1 (23.7-28.4)

Symptoms

 Asymptomatic (0)

4409

888

20.1 (19.0-21.3)

20.86 (18.86-22.85)

29.0 (26.2-31.9)

27.0 (24.6-29.5)

< 0.0001

 Paucisymptomatic (1-3)

1797

398

22.1 (20.2-24.1)

21.77 (17.10-26.44)

32.9 (26.2-39.7)

30.6 (24.6-36.7)

 Symptomatic (≥4)

1149

460

40.0 (37.2-42.9)

37.5 (28.68-46.32)

61.0 (47.2-74.7)

56.8 (44.2-69.3)

  1. Seroprevalence data are % (95% confidence interval). aWeighted for age, sex and city population. bWeighted prevalence adjusted for test performance I (sensitivity 66·9% and specificity 98.2%). cWeighted prevalence adjusted for test performance II as reported by manufacturer (sensitivity 71.8% and specificity 98.2%). When a variable was stratified it was removed from the weight
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us